TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32253896

Group type: EXPERIMENTAL
Intervention: Functional multicomponent training (MFT), N=15
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Traditional multicomponent training (MTT), N=14
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (CG), N=8
Number of subjects: 37
Study: 35373687

Group type: EXPERIMENTAL
Intervention: Ida My Hearing Explained Tool (IMHET)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Audiogram
Number of subjects: 51
Study: 34574738

Group type: EXPERIMENTAL
Intervention: Wearable activity tracker
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Wearable device characteristics
Number of subjects: 11

Group type: COMPARATOR
Intervention: Questionnaire scores
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Device acceptability level
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthcare professionals' perception
Number of subjects: 11
Study: 32270959

Group type: EXPERIMENTAL
Intervention: Abdominal exercises with upper limb movements (ARM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Abdominal activation with leg movements (LEG)
Number of subjects: 20
Study: 36085065

Group type: EXPERIMENTAL
Intervention: Guided meditation (Yoganidra) for 6 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no guided meditation)
Number of subjects: 80
Study: 34826381

Group type: EXPERIMENTAL
Intervention: CVnCoV (12 μg of mRNA, two 0.6 mL doses, days 1 and 29)
Number of subjects: 39680

Group type: EXPERIMENTAL
Intervention: CVnCoV
Number of subjects: 39680

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl, two 0.6 mL doses, days 1 and 29)
Number of subjects: 39680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39680
Study: 33246159

Group type: EXPERIMENTAL
Intervention: Frequentist linear mixed effect (LME) modelling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical modelling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crude change
Number of subjects: 0

Group type: COMPARATOR
Intervention: SEKOIA JSW change
Number of subjects: 0

Group type: COMPARATOR
Intervention: OAI JSW change
Number of subjects: 0
Study: 32133780

Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg oral daily from the first trimester
Number of subjects: 1790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Low-risk group (no specific intervention mentioned)
Number of subjects: 1790
Study: 34267115

Group type: EXPERIMENTAL
Intervention: PFCL-assisted drainage through preexisting break
Number of subjects: 52

Group type: COMPARATOR
Intervention: Posterior retinotomy to drain subretinal fluid
Number of subjects: 52
Study: 33603941

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with remifentanil and propofol (n = 35)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Volatile Anesthesia (VA) with propofol induction and maintenance with desflurane and nitrous oxide (n = 37)
Number of subjects: 72
Study: 32994235

Group type: EXPERIMENTAL
Intervention: Implementation programme for the MRF service
Number of subjects: 222
Study: 35078079

Group type: EXPERIMENTAL
Intervention: Partial-oral treatment
Number of subjects: 400

Group type: COMPARATOR
Intervention: Intravenous treatment
Number of subjects: 400
Study: 32150762

Group type: EXPERIMENTAL
Intervention: macitentan
Number of subjects: 85

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study: 36050653

Group type: EXPERIMENTAL
Intervention: Nivolumab after temozolomide treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks)
Number of subjects: 18
Study: 33730151

Group type: EXPERIMENTAL
Intervention: Methadone/Ketamine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 130
Study: 32088302

Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G‐CSF) administered for 5 days every 3 months for 4 cycles (group A, n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard medical therapy alone (group B, n = 50)
Number of subjects: 100
Study: 32243907

Group type: COMPARATOR
Intervention: IP-sham
Number of subjects: 69

Group type: COMPARATOR
Intervention: RP-sham
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: IP-cathodal tDCS
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: RP-anodal tDCS
Number of subjects: 69
Study: 35063311

Group type: EXPERIMENTAL
Intervention: SKIP‐IT intervention (narrative and picture‐based smoking cessation intervention delivered via text messages)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28
Study: 33367833

Group type: EXPERIMENTAL
Intervention: Bright IDEAS (BI) problem-solving skills training (PSST)
Number of subjects: 154
Study: 35972531

Group type: EXPERIMENTAL
Intervention: 3 mg/kg of caffeine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 6 mg/kg of caffeine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 18
Study: 34151724

Group type: EXPERIMENTAL
Intervention: internet-based Cognitive Behavioral Therapy (iCBT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 10
Study: 36190062

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 gm intravenously 30 minutes before surgery)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 34294807

Group type: EXPERIMENTAL
Intervention: 35% red shading screen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 35% black shading screen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 35% silver shading screen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full sun control
Number of subjects: 0
Study: 32588919

Group type: EXPERIMENTAL
Intervention: Progressive resistance training of the ankle plantarflexors (30 sessions: 10 supervised and 20 unsupervised home sessions over 10 weeks)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Progressive resistance training of the ankle plantarflexors
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study: 34410011

Group type: EXPERIMENTAL
Intervention: Cardiac Care Bridge (CCB) intervention
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 306
Study: 33543267

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Polar Breeze thermal rehabilitation machine (PB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive rest (PASS)
Number of subjects: 12
Study: 32560634

Group type: EXPERIMENTAL
Intervention: TPRK
Number of subjects: 126

Group type: COMPARATOR
Intervention: FS-LASIK
Number of subjects: 126
Study: 35403350

Group type: EXPERIMENTAL
Intervention: Exenatide XR 2.0 mg weekly
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Exenatide XR vs Placebo
Number of subjects: 100
Study: 33291700

Group type: EXPERIMENTAL
Intervention: Chili (2 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35387718

Group type: EXPERIMENTAL
Intervention: Cecal ligation and puncture (CLP) model
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 2
Study: 32146123

Group type: EXPERIMENTAL
Intervention: Water irrigant
Number of subjects: 121

Group type: COMPARATOR
Intervention: Saline irrigant
Number of subjects: 121
Study: 32748028

Group type: EXPERIMENTAL
Intervention: Genetically predicted reduction in HbA1c (%) instrumented by AMPK variants
Number of subjects: 391199
Study: 34686616

Group type: EXPERIMENTAL
Intervention: Single CHO mouth rinse (8% maltodextrin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eight CHO mouth rinses (8% maltodextrin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo solution (noncaloric juice)
Number of subjects: 12
Study: 35950489

Group type: EXPERIMENTAL
Intervention: Pelabresib + ruxolitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + ruxolitinib
Number of subjects: 0
Study: 35280154

Group type: EXPERIMENTAL
Intervention: Short‐Term Assessment of Risk and Treatability (START)
Number of subjects: 50
Study: 33539915

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Individual and Group Supportive Therapy (IGST)
Number of subjects: 173
Study: 33320868

Group type: EXPERIMENTAL
Intervention: NO3‐ rich beetroot juice (12.4 mmol NO3‐)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Positive-control (140 ml of water)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo-trial (140 ml NO3‐ depleted beetroot juice)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Negative-control (140 ml of water)
Number of subjects: 11
Study: 35388235

Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine 1.0 mg/kg body weight (BW), q12h for 14 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nebulized budesonide 1 μg/kg, q12h for 14 days
Number of subjects: 19
Study: 35028769

Group type: EXPERIMENTAL
Intervention: VS+PBMT (vaginal stretching combined with photobiomodulation therapy)
Number of subjects: 103

Group type: COMPARATOR
Intervention: VS+shamPBMT (vaginal stretching combined with sham photobiomodulation therapy)
Number of subjects: 103
Study: 33575340

Group type: EXPERIMENTAL
Intervention: Hospital-based systemic rehabilitation (50-minute sessions, three times weekly for 12 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Hospital-based systemic rehabilitation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Education-based rehabilitation at home
Number of subjects: 35
Study: 33405346

Group type: EXPERIMENTAL
Intervention: Mislabeled objects during encoding context
Number of subjects: 20

Group type: COMPARATOR
Intervention: Correctly labeled objects during encoding context
Number of subjects: 20
Study: 32292360

Group type: EXPERIMENTAL
Intervention: Drug plus psychotherapy (DPP) - olanzapine and metacognitive training
Number of subjects: 41

Group type: COMPARATOR
Intervention: Drug therapy (DT) - olanzapine only
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: DPP group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 41
Study: 34510258

Group type: EXPERIMENTAL
Intervention: Surgery with neoadjuvant radiotherapy (29%)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Surgery with adjuvant radiotherapy (37%)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Monotherapy with surgery (22%)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy (7%)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Radiotherapy (5%)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Overall treatment (80% completed treatment with curative intent)
Number of subjects: 226
Study: 35221683

Group type: EXPERIMENTAL
Intervention: Integrated Disease Management (IDM) intervention
Number of subjects: 571
Study: 32855884

Group type: EXPERIMENTAL
Intervention: Electroretinography (ERG)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Standard Automated Perimetry
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Color Discrimination
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: ERG Amplitudes and Isopter Area
Number of subjects: 97
Study: 34897226

Group type: EXPERIMENTAL
Intervention: Oral Naltrexone (NTX)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 32330571

Group type: EXPERIMENTAL
Intervention: Riboflavin (1.6 mg/d) for 16 weeks, n=24
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo, n=23
Number of subjects: 115
Study: 36249252

Group type: EXPERIMENTAL
Intervention: Fully vaccinated individuals (n = 1114)
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Sinopharm vaccine
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Cansino vaccine
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Sinovac vaccine
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Vaccinated individuals (n = 1114)
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Breakthrough cases in men
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Age group 18-33 years
Number of subjects: 2467
Study: 32019609

Group type: EXPERIMENTAL
Intervention: 12-week RUFIT-NZ program
Number of subjects: 308

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 308
Study: 32167792

Group type: EXPERIMENTAL
Intervention: Fish oil (2100 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 56
Study: 33392664

Group type: EXPERIMENTAL
Intervention: HEMOCIN® patch
Number of subjects: 64

Group type: COMPARATOR
Intervention: No systematic treatment (control)
Number of subjects: 64
Study: 32889172

Group type: EXPERIMENTAL
Intervention: Local p16 testing by immunohistochemistry (IHC)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: HPV RNA in situ hybridisation (HPV RNA ISH)
Number of subjects: 176
Study: 36684501

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 300 mg/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 33921935

Group type: EXPERIMENTAL
Intervention: ViroTrack Dengue Serostate
Number of subjects: 484
Study: 32376341

Group type: EXPERIMENTAL
Intervention: Resting-state EEG recordings and dynamic analysis of design fluency test
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Theta-band hyper-connections
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Baseline hyperconnectivity within the posterior hub of the Default Mode Network
Number of subjects: 34
Study: 36123783

Group type: EXPERIMENTAL
Intervention: EMP16-120/40 (120 mg orlistat/40 mg acarbose)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: EMP16-150/50 (150 mg orlistat/50 mg acarbose)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 33359193

Group type: EXPERIMENTAL
Intervention: Outpatient PCI
Number of subjects: 1905

Group type: COMPARATOR
Intervention: Inpatient PCI
Number of subjects: 1905
Study: 33639331

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) for OCD
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) for MDD
Number of subjects: 110

Group type: COMPARATOR
Intervention: Deep brain stimulation (DBS) for OCD and MDD
Number of subjects: 110
Study: 32934372

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Propensity score–matched controls
Number of subjects: 39
Study: 35775199

Group type: EXPERIMENTAL
Intervention: Housing insecurity (i.e., foreclosure/eviction threat, history of homelessness, late rent)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Household crowding
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Breastfeeding exclusivity intention during the early postnatal period
Number of subjects: 361
Study: 33821768

Group type: EXPERIMENTAL
Intervention: IBU monotherapy
Number of subjects: 1477

Group type: EXPERIMENTAL
Intervention: APAP monotherapy
Number of subjects: 1477
Study: 34748059

Group type: EXPERIMENTAL
Intervention: Intratumoral (IT) tracer injection (2 depots of 1 mL indocyanine green-[99mTc]Tc-nanocolloid)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Intraprostatic (IP) tracer injection (4 depots of 0.5 mL indocyanine green-[99mTc]Tc-nanocolloid)
Number of subjects: 113
Study: 32558047

Group type: EXPERIMENTAL
Intervention: mini-CEX rating form
Number of subjects: 36
Study: 34488392

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation guided by POEM score >3
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard monitoring without POEM score
Number of subjects: 31
Study: 32367880

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) for 5 days a week for 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Extracorporeal Shock Wave therapy (ESWT) once a week for 3 weeks
Number of subjects: 40
Study: 35279948

Group type: EXPERIMENTAL
Intervention: HARD (Restylane Defyne with lidocaine)
Number of subjects: 173

Group type: COMPARATOR
Intervention: HAR (Restylane, the gold standard HA filler)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: HARD
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: HARD and HAR
Number of subjects: 173
Study: 34516492

Group type: EXPERIMENTAL
Intervention: FIO2 > 0.85
Number of subjects: 42

Group type: COMPARATOR
Intervention: FIO2 < 0.7
Number of subjects: 42
Study: 32150855

Group type: EXPERIMENTAL
Intervention: UVB group (half‐body UVB irradiation, twice weekly over 6 months, with 1 standard erythema dose (SED))
Number of subjects: 78

Group type: COMPARATOR
Intervention: VD group (5600 International units (IU) cholecalciferol supplementation once a week)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups (UVB and VD)
Number of subjects: 78
Study: 35973626

Group type: EXPERIMENTAL
Intervention: Local prophylactic antibiotic therapy with vancomycin loaded calcium sulfate beads
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional IV prophylactic antibiotic therapy
Number of subjects: 83
Study: 33888426

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 51
Study: 34628439

Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA)
Number of subjects: 2406

Group type: COMPARATOR
Intervention: Usual procedures (Control)
Number of subjects: 2406
Study: 33862000

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, fluorouracil 2400 mg/m2 intravenously every 14 days for 6 cycles), followed by chemoradiotherapy (50 Gy during 5 weeks and 800 mg/m2 concurrent oral capecitabine twice daily for 5 days per week), total mesorectal excision, and adjuvant chemotherapy (3 months of modified FOLFOX6 or capecitabine).
Number of subjects: 461

Group type: COMPARATOR
Intervention: Standard-of-care (chemoradiotherapy, total mesorectal excision, and adjuvant chemotherapy for 6 months).
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (during neoadjuvant chemotherapy).
Number of subjects: 461

Group type: COMPARATOR
Intervention: Standard-of-care group (during chemoradiotherapy).
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (during adjuvant chemotherapy).
Number of subjects: 461

Group type: COMPARATOR
Intervention: Standard-of-care group (during adjuvant chemotherapy).
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (serious adverse events during the whole treatment period).
Number of subjects: 461

Group type: COMPARATOR
Intervention: Standard-of-care group (serious adverse events during the whole treatment period).
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (serious adverse events during adjuvant therapy).
Number of subjects: 461

Group type: COMPARATOR
Intervention: Standard-of-care group (serious adverse events during adjuvant therapy).
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (treatment-related deaths).
Number of subjects: 461

Group type: COMPARATOR
Intervention: Standard-of-care group (treatment-related deaths).
Number of subjects: 461
Study: 34273650

Group type: EXPERIMENTAL
Intervention: Black chokeberry dried pomace (30 g/kg of feed)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Black currant dried pomace (30 g/kg of feed)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Raspberry dried pomace (30 g/kg of feed)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 480
Study: 32629992

Group type: EXPERIMENTAL
Intervention: Oat β‐glucan (12g/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Wheat arabinoxylan (12g/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 49
Study: 35359769

Group type: EXPERIMENTAL
Intervention: Chinese version of the Brief State Rumination Inventory (BSRI)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Rumination induction group (n=27)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Distraction group (n=27)
Number of subjects: 512
Study: 35368495

Group type: EXPERIMENTAL
Intervention: After-school physical activity intervention for 9 months
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 280
Study: 33427961

Group type: EXPERIMENTAL
Intervention: 600 IU vitamin D3/day
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3/day
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3/day
Number of subjects: 378
Study: 34533848

Group type: EXPERIMENTAL
Intervention: Alcohol expectancies for sociability, sexuality, and risk/aggression
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Alcohol expectancies for self-perception
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Valuation of risk/aggression
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Alcohol expectancies for sexuality and self-perception
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Valuation of self-perception
Number of subjects: 433
Study: 32052116

Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy (PRRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hybrid SSTR-SPECT/CT or -PET/CT
Number of subjects: 0
Study: 33065729

Group type: EXPERIMENTAL
Intervention: Passive exposure to blue‐enriched polychromatic lighting for three 20‐minute intervals including 10 minutes of exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study: 32078815

Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV alone at weeks 0 and 12 and Ad26.Mos.HIV plus adjuvanted gp140 at weeks 24 and 48 (Group 1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV plus adjuvanted gp140 at weeks 0, 12, and 24 (Group 2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV alone at week 0 and Ad26.Mos.HIV plus adjuvanted gp140 at weeks 8 and 24 (Group 3)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (0.5 mL of 0.9% saline)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All vaccine regimens
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Shortened group 3 regimen in rhesus monkeys
Number of subjects: 36
Study: 35661378

Group type: EXPERIMENTAL
Intervention: TTP399 (800 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23